Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Low dose Iloprost effect on platelet aggregation in comatose out-of-hospital cardiac arrest patients: A predefined sub-study of the ENDO-RCA randomized -phase 2- trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Narrative critical care: A literary analysis of first-person critical illness pathographies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The search for the holy grail continues: The difficult journey towards the ideal fluid!

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mean arterial pressure during targeted temperature management and renal function after out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lipidomic Signatures Align with Inflammatory Patterns and Outcomes in Critical Illness

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: This is a predefined sub-study of the Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA) trial. We aim to investigate Iloprost, a prostacyclin analogue, safety by evaluating change in whole blood platelet aggregometry (Multiplate) in out of hospital cardiac arrest (OHCA) patients from baseline to 96-h post randomization.

METHODS: A randomized, placebo controlled double-blinded trial in 46 OHCA patients. Patients were allocated 1:2 to 48 h Iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Platelet aggregation was determined by platelet aggregation tests ASPI-test (arachidonic acid); TRAP-test (thrombin-receptor activating peptide (TRAP)-6; RISTO test (Ristocetin); ADP test (adenosin diphosphat).

RESULTS: There was no significant difference between the iloprost and placebo groups according to ASPI, TRAP, RISTO and ADP platelet aggregation assays. Further, no significant differences regarding risk of bleeding were found between groups (Risk of bleeding: ASPI <40 U; TRAP <92 U; RISTO <35 U; ADP <50 U).

CONCLUSIONS: In conclusion, the iloprost infusion did not influence platelet aggregation as evaluated by the ASPI, TRAP, RISTO and ADP assays. There was no increased risk of bleeding or transfusion therapy. A decline in platelet aggregation was observed for the ASPI and ADP assays during the initial 96 h after OHCA.

TRIAL REGISTRATION: Trial registration at clinicaltrials.gov (identifier NCT02685618) on 18-02-2016.

Original languageEnglish
JournalJournal of Critical Care
Volume56
Pages (from-to)197-202
Number of pages6
ISSN0883-9441
DOIs
Publication statusPublished - Apr 2020

ID: 61783997